口服灭活多价产肠毒素大肠杆菌疫苗ETVAX在人体诱导的抗体交叉反应与亲和力
研究分析了两项I期试验中口服灭活多价产肠毒素大肠杆菌(ETEC)疫苗ETVAX诱导的抗体交叉反应与亲和力,疫苗含过表达定植因子CFA/I、CS3、CS5、CS6的四株大肠杆菌及类毒素LCTBA。结果显示,对CFA/I应答者中65-90%产生针对CS1、CS14、CS17的交叉反应抗体,对CS5应答者中约80%对CS7应答;加强接种后血清和ALS抗体亲和力较初免升高。
要点
- 对CFA/I应答者中65-90%产生针对CS1、CS14、CS17的交叉反应抗体。
- 对CS5应答者中约80%产生针对CS7的交叉反应抗体。
- 晚期加强剂量后血清和ALS抗体亲和力较初免升高。
核心结论
- 针对多种定植因子的交叉反应抗体反应可能扩大ETVAX的ETEC菌株覆盖范围。
- 重复接种可诱导结合能力增强的疫苗特异性抗体。
研究设计与样本
- 分析两项I期试验的黏膜(粪便和ALS)样本及血清、ALS样本。
- 初免研究:间隔2周口服两剂ETVAX,±dmLT佐剂。
- 加强研究:初免后13-23个月给予单剂ETVAX加强。
主要发现
- 对CFA/I在ALS或粪便标本中应答的受试者中65-90%也产生针对CS1、CS14和CS17的交叉反应抗体。
- 对CS5应答者中约80%也对密切相关的CS7应答。
- 已产生交叉反应抗体的受试者中,针对疫苗CF和相关非疫苗CF的反应幅度相当。
- 采用限制抗原稀释法和离液序列ELISA法均发现,血清和ALS抗体对关键疫苗抗原的亲和力在晚期加强剂量后较初免后升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated whether the oral inactivated, multivalent enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX, consisting of four E. coli strains over-expressing the colonisation factors (CFs) CFA/I, CS3, CS5 and CS6, combined with the toxoid LCTBA, could induce cross-reactive antibodies to CFs related to the CFA/I and CS5 families. We also evaluated the avidity of vaccine induced antibodies against the toxoid and CFs. Cross-reactivity was analysed in mucosal (faecal and antibodies in lymphocyte supernatants, ALS) samples, and antibody avidity in serum and ALS samples, from two phase I trials: a primary vaccination study, where two oral doses of ETVAX were given±the double mutant heat labile toxin (dmLT) adjuvant at a 2-week interval, and a booster vaccination study, where a single booster dose of ETVAX was given 13-23months after primary vaccinations. We found that 65-90% of subjects who had responded to CFA/I in ALS or faecal specimens also developed cross-reactive antibodies to the related CFs tested, i.e. CS1, CS14 and CS17, and that approximately 80% of those responding to CS5 also responded to the closely related CS7. For subjects who had developed cross-reactive antibodies, the magnitudes of responses against vaccine CFs and related non-vaccine CFs were comparable. Using both a simple method of antibody avidity determination based on limiting antigen dilution, as well as a chaotropic ELISA method, we found that the avidity of serum and ALS antibodies to key vaccine antigens increased after a late booster dose compared to after primary vaccination. Our results suggest that the cross-reactive antibody responses against multiple CFs may result in expanded ETEC strain coverage of ETVAX and that repeated vaccinations induce vaccine-specific antibodies with increased binding capacity.
引用
- Leach S, Lundgren A, Carlin N, et al. Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenicEscherichia coli (ETEC) vaccine ETVAX. Vaccine. 2017. PMID: 28625524. doi:10.1016/j.vaccine.2017.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。